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Abstract: We experienced a case of 59-year-old woman with intractable asthma, who had
aspirin intolerance. Despite various treatments inclUding systemic corticosteroid admin-
istration, she was often admitted due to severe asthma attacks. Furthermore, she had
allergic rhinitis and sinusitis. Computed tomography (CT) scans of sinonasal cavity
revealed marked thickness of nasal mucosa and air-fluid level in maxillary sinuses.
Although her asthma symptoms such as Wheezing and dyspnea were improved by
administration of bronchodilator, systemic corticosteroids and beclomethasone di-
isoccyanate (BDI) accompanied with spa therapy, her peak expiratory flow (PEF) showed
no improvement. After readmission due to asthma attacks, clarithromycin (CAM)
administration for sinonasal disorders was started. The PEF value showed marked
improvement after starting CAM administration, and pulmonary functions and bronchial
hyperresponsiveness were also improved. It is suggested from her clinical course that
CAM may have beneficial effects in asthmatic patients with sinonasal disorders.
Key word: bronchial asthma, allergic rhinitis, sinusitis, clarithromycin, peak expiratory
flow (PEF)
Introduction
Bronchial asthma is often accompanied with allerg-
ic rhinitis or chronic sinusitis. It has been suggested
that treatment of nasal allergy can help to reduce
airway responses in some patients with asthma. Rac-
helefsky et a1. examined the influence of medical
therapy for sinusitis on airway response in 48 children
with asthma. They showed that a marked improvement
in asthma symptoms, normalization of pulmonary
function tests in 67% of patients, and discontinuation
of bronchodialator use in 79% of patients were
observed I). Similar results were reported by Friedman,
et al.2) and Slavin3). However, the influence of si-
nonasal disease on pathogenesis of asthma is poorly
understood. Two previous controlled studies have
shown a reduction in asthma symptoms and imp-
rovement in bronchial hyperresposiveness during pol-
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len seasons with the use of intranasal corticosteroids4.5?
These data suggest that there may be a relationship in
inflammatory events between the upper and lower
airways, and that sinusitis may have influences on
asthma exacerbation. In this article, we reported a case
with aspirin-induced asthma whose pulmonary func-
tions were improved by the treatment for sinusitis.
Case Report
A 59-year-old woman was admitted at the Misasa
Medical Branch on October 28, 1997, because of
asthma attacks. She had no dyspnea until the age of
39. At the age of 39, she was first aware of shortness
of breath and wheeze. She had subsequently consulted
a doctor, and was diagnosed as bronchial asthma.
Since then, she had been admitted many times due to
severe asthma attacks. Several years later, it was
revealed that she had aspirin-intolerance and allergic
rhinitis. For several days before this admission, she
developed sore throat, cough and dyspnea, and on
admission day, she had still severe asthma attacks.
Physical examination on admission revealed ex-
piratory and inspiratory dry rales over the all lung
fields and prolonged expiration on auscultation. The
findings of blood chemistry and urinalysis were
normal. The serum IgE level was 93.0 Ulml and
specific antibodies for Dermatophagoides pteronys-
sinus, Dermatophagoides farinae, Candida, cat-skin
and rice pollen were positive by radioallergosorbent
test (RAST). Chest X-ray film showed normal find-
ings. Systemic corticosteroids and bronchodilators
were administered after admission. Improvement of
asthma attacks was observed by the ninth hospital day.
On the 18th hospital day she started to have complex
spa therapy (swimming training at a hot spring,
inhalation of iodine salt solution and fango therapy),
with 7.5mg/day of systemic corticosteroid, inhaled
glucocorticoid (beclomethasone) and bronchodilators
administration. Results of pulmonary function test at
the 30th hospital day were as follows; %VC 92.5%,
FEVI.O% 57.5%, %V75 45.6%, %V50 16.0%, %V25
4.5% and %DLCO 158.7%. Despite gradual improve-
ment of subjective symtoms, the peak expiratory flow
(PEF) in the early morning did not improve (160-
21OUmin, average 194.5Um). She was discharged on
February 10,1998.
She was readmitted on March 11, 1998, because of
severe asthma attacks. In the physical examinations,
marked expiratory dry rales were heard over the lung
fields on auscultation. Initial laboratory data on re-
admission are shown in Table 1. The clinical course
during readmission is illustrated in Fig.1. She was
treated with systemic corticosteroid and broncho-
dilators were after admission. Although wheeze and
dyspnea diminished by the ninth hospital day, promi-
nent nasal and post-nasal discharge were not im-
proved. Chest CT scans revealed neither signs of
emphysema, chronic bronchitis nor middle lobe syn-
drome. Sinonasal CT scans revealed marked thicken-
ing of bilateral nasal mucosa and air-fluid level in
bilateral maxillary sinuses (Fig.2). Results of pul-
monary function test at the 16th hospital day were as
follows; %VC 95.0%, FEVI.O% 67.8%, %V75 7.2%,
%V50 26.7%, %V25 11.7% and %DLCO 123.5%.
Bronchial responsiveness was measured using met-
hacholine with an Astograph (Chest Corp., Tokyo,
Japan), and she revealed bronchial hyperresponsive-
ness (Cmin 98 y Iml, Dmin 0.0621 units). To control
nasal and post-nasal discharge, clarithromycin (CAM)
was administered on the 14th hospital day. After
administration of CAM, nasal and post-nasal discharge
gradually decreased, accompanied with improvement
of the value of PEF metry. The pulmonary function
test at the 77th hospital day improved as follows;
%VC 100.4%, FEVI.O% 61.4%, %V75 63.3%, %V50
21.8%, %V25 12.0% and %DLCO 157.9%. Airway
hyperresponsiveness also showed improvement after
CAM administration (Cmin 390 y ImI, Dmin 0.394
units)(Table 2).
Discussion
It has been noted since the time of Galen that an
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100
300
before after
FVC 2210ml(92.S%) 241 Oml(1 00.4%)
FEV10 1270ml(S7.S%) 1480ml(61.4%)
MMF 0.74Us(28.2%) 1.04L1s(39.S%)
PEFR 3.04Us(SS.1 %) 3.25Us(58.6%)
ins 2.33Us(45.6%) 3.24Us(63.3%)
VSO 0.60Us(16.0%) 0.82Us(21.8%)
V25 o 07Us( 4.S%) 0.19Us(12.0%)
Cmin 98y/ml 39Qy/ml
Omin 0.0621unit 0.394unit
association exists between nasal symptoms and chest
disease6). More recently, Several studies have sug-
gested that there is a link between upper respiratory
tract disorders and bronchial asthma7.8.9.IO.II). Furt-
hermore, many investigators have noted that treatment
of upper airway disease often resulted in an imp-
rovement of asthma symptoms I2.13). In our case,
administration of CAM for sinusitis and allergic
rhinitis resulted in improvement of sinonasal dis-
charge, pulmonary functions and bronchial hyper-
responsiveness. The improvement of them may be due
to the results of decrease of post-nasal discharge.
Huxley et al. reported that pulmonary aspiration of
nasopharyngeal secretions could be found in 50% of
normal subjects and 70% of ill patients because of
relaxation of the epiglollis during sleep I4). In patients
with chronic sinusitis, eosinophil infiltration in sinus
mucosa has often been observed, and extracellular
deposition of major basic protein (MBP) has also been
shown to correlate with mucosal damage I5). Eo-
sinophils in post-nasal discharge aspirated into airways
may induce the damage of bronchial mucosa and lead
to asthma exacerbation. CAM has the effects that
reduce naso-sinus secretion and increase mucocilliary
transportation 16) Reduce of post-nasal discharge and
aspiration into airway by CAM may lead to imp-
rovement of bronchial inflammation in our case. The
improvement of asthma symptoms in our case may
Table 2. Changes of pulmonary functions and bronc-
hial responsi veness before and after clarith-
romycin administration
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Fig. 2 CT scan of the sinus level. Marked thickness of
nasal mucosa and air-fluid level in maxillary
sinuses were observed.
Fig. I clinical course of patient during readmission
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also be due to the result of improved nasal filtering by
administration of CAM17).
Another proposed mechanism for the role of si-
nusitis as an aggravator of asthma is nasal-sinus-
bronchial reflex. Kaufman and Wright showed an
increase in lower airway resistance by blowing silica
particles into the nasopharynx. In contrast, atropin
injection inhibited lower airway response. Stimulation
of neural receptors in the nose and sinuses activates
trigeminal afferent pathways and produces bronc-
hoconstriction through a vagal efferent neural arc I8). In
our case, chronic inflammation in maxillary sinuses
might be relieved by CAM administration, and stimu-
lation of sinonasal receptors might decrease. Further-
more, CAM may inhibit cholinergic neuroeffector
transmission in the human airway smooth muscle by
reducing exocytotic release of acetylcholine from the
nerve terminals 19).
CAM has also the effects of attenuation cytokine-
induced endotheline-l expression in human bronchial
epithelial cells201, induction of eosinophil apoptosis21 )
and protection of ciliated epithelium against oxidative
damage inflicted by phospholipids-sensitized pha-
gocytes221• Besides improvement of sinonasal symp-
toms, these effects for airway might result in improve-
ment of pulmonary functions and bronchial hyper-
responsiveness in our case.
From the course of this case, c1arithromycin may
have beneficial effects in asthmatic patients with
chronic sinusitis or allergic rhinitis.
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鼻腔 ･副鼻腔疾患を合併する気管支端息症例に対
するクラリスロマイシン投与の効果
御船尚志,光延文裕,保崎泰弘,芦田耕三,柘野
浩史,原田誠之,岡本 誠,湯本英一朗,高田真
吾,谷崎勝朗
岡山大学医学部附属病院三朝分院内科
気管支鴨息にアレルギー性鼻炎や副鼻腔炎を合
併する症例は頻回に経験される｡副鼻腔炎症状の
増悪が鴨息症状の増悪を引き起こす症例も存在し,
鼻腔 ･副鼻腔における炎症が気管支犠息の病態と
何らかの関係を持っていることが考えられる｡今
62
回,59才の難治性アスピリン噂息症例を呈示す
る｡副腎皮質ホルモンの全身投与を含めた様々な
治療にも関わらず頻回に重篤な嘱息発作を呈し,
入退院を繰り返している症例である｡アレルギー
性鼻炎も合併し,CTでは著明な鼻粘膜肥厚と上
顎洞の鏡面形成が認められた｡入院後の投薬や温
泉療法によって呼吸困難は改善したが,ピークフ
ロー値は上昇が認められないまま退院となった｡
再入院後,副鼻腔炎に対しクラリスリマイシン投
与を開始したところ､ピークフロー値は著明に改
善を示し,肺機能 ･気道過敏性も改善した｡この
症例のように,鼻腔 ･副鼻腔疾患を合併する気管
支喋息症例に対しては,クラリスロマイシン投与
が有効である可能性が考えられた｡
